System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Letter Ahead of print

PubMed: 42570933 DOI: 10.1016/j.ejim.2026.107114

Comparable 1-year effectiveness of tezepelumab and dupilumab after anti-IL-5/IL-5Rα biologic failure in severe asthma.

Eur J Intern Med

Authors: Po-Cheng Shih, Shih-Pin Chen, James Cheng-Chung Wei

Affiliations

  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division of Chest Medicine, Department of internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan; Office of Research and Development, Asia University, Taichung, Taiwan; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan; Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.

MeSH

Interleukin-5, Asthma